SCHEMBL3821055

SCHEMBL3821055

CCC(CC)c1cccc(C(=O)O)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
SLC37A4 O43826 1/20 0.43
ALDH1A1 P00352 4/20 0.40
ALOX15 P16050 1/20 0.40
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
MAPT P10636 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
CLCN2 P51788 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 4/20 0.38
GAA P10253 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
MEN1 O00255 2/20 0.37
RECQL P46063 1/20 0.37
FOLH1 Q04609 1/20 0.37
AKR1C3 P42330 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25220694 0.92 POLB (0.42) POLBSLC37A4ALDH1A1ALOX15KDM4E
Water SCHEMBL27890364 0.90 POLB (0.41) POLBSLC37A4ALDH1A1ALOX15KDM4E
SCHEMBL409572 0.90 SLC37A4 (0.45) POLBSLC37A4ALDH1A1ALOX15KDM4E
SCHEMBL15281935 0.88 SLC37A4 (0.41) POLBSLC37A4ALDH1A1ALOX15KDM4E
SCHEMBL990486 0.87 POLB (0.46) POLBSLC37A4ALDH1A1ALOX15KDM4E
SCHEMBL1134750 0.86 SLC37A4 (0.54) POLBSLC37A4ALDH1A1KDM4EKMT2A
SCHEMBL7942880 0.85 SLC37A4 (0.53) SLC37A4ALDH1A1KDM4EKMT2AMEN1
SCHEMBL7944631 0.85 SLC37A4 (0.53) SLC37A4ALDH1A1KDM4EKMT2AMEN1
SCHEMBL7942873 0.85 SLC37A4 (0.53) SLC37A4ALDH1A1KDM4EKMT2AMEN1
SCHEMBL5695797 0.84 POLB (0.44) POLBSLC37A4ALDH1A1ALOX15KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368057-B1 METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN TORREY PINES INST (US) 2009-08-26 EP claimed
US-7229621-B2 Method to enhance the immunogenicity of an antigen TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 2007-06-12 US claimed
EP-1071411-B1 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INST (US) 2007-03-14 EP claimed
EP-1071411-A4 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INST (US) 2004-12-08 EP claimed
EP-1368057-A2 METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN Lancell, Llc (US) 2003-12-10 EP claimed
WO-2002074332-A2 METHOD TO ENHANCE THE IMMUNOGENICITY OF AN ANTIGEN LANCELL, LLC (US) 2002-09-26 WO claimed
US-20010024649-A1 Method to enhance the immunogenicity of an antigen TORREY PINES INSTITUTE FOR MOLECULAR STUDIES 2001-09-27 US claimed
US-6210672-B1 TOPICAL ADMINISTRATION OF AN ANTIGEN OR A PORTION THEREOF IN CONJUNCTION WITH AN ENHANCER OF SKIN PENETRATION AND AN INDUCER OF LANGERHANS CELL MIGRATION. TORREY PINES INSTITUTE FOR MOLECULAR STUDIES 2001-04-03 US claimed
EP-1071411-A1 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 2001-01-31 EP claimed
WO-1999053912-A1 TOPICAL IMMUNOSTIMULATION TO INDUCE LANGERHANS CELL MIGRATION TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) 1999-10-28 WO claimed
US-4829037-A STEREOREGULAR POLYMER IN HIGH YIELD TOHO TITANIUM CO., LTD. (JP) 1989-05-09 US claimed
EP-0268685-A1 CATALYST FOR POLYMERIZING OLEFINS TOHO TITANIUM CO. LTD. (JP) 1988-06-01 EP claimed
US-4562173-A MAGNESIUM FATTY ACID SALT, MAGNESIUM CARBONATE COMPOUND, AROMATIC DICARBOXYLIC ACID ESTER, TITANIUM HALIDE, SILICON COMPOUND, ORGANOA TOHO TITANIUM CO., LTD. (JP) 1985-12-31 US claimed
US-4547476-A COORDINATION CATALYST CONTAINING MAGNESIUM, TITANIUM, ALUMINUM ANDSILICON COMPOUNDS, AROMATIC ESTER AND HALOGENATED COMPOUNDS TOHO TITANIUM CO., LTD. (JP) 1985-10-15 US claimed
US-20150307938-A1 METHOD TO IDENTIFY A NOVEL CLASS OF IMMUNOLOGIC ADJUVANTS LANCELL L L C (US) 2015-10-29 US disclosed
WO-2012138928-A1 METHOD TO IDENTIFY A NOVEL CLASS OF IMMUNOLOGIC ADJUVANTS LANCELL, L.L.C. (US) 2012-10-11 WO disclosed
US-20120258125-A1 METHOD TO IDENTIFY A NOVEL CLASS OF IMMUNOLOGIC ADJUVANTS LANCELL, L.L.C. (US) 2012-10-11 US disclosed
EP-0268685-A1 CATALYST FOR POLYMERIZING OLEFINS TOHO TITANIUM CO. LTD. (JP) 1988-06-01 EP disclosed
US-4562173-A MAGNESIUM FATTY ACID SALT, MAGNESIUM CARBONATE COMPOUND, AROMATIC DICARBOXYLIC ACID ESTER, TITANIUM HALIDE, SILICON COMPOUND, ORGANOA TOHO TITANIUM CO., LTD. (JP) 1985-12-31 US disclosed
US-4547476-A COORDINATION CATALYST CONTAINING MAGNESIUM, TITANIUM, ALUMINUM ANDSILICON COMPOUNDS, AROMATIC ESTER AND HALOGENATED COMPOUNDS TOHO TITANIUM CO., LTD. (JP) 1985-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010024649-A1 Method to enhance the immunogenicity of an antigen CD69, CD74, LY96 POLB 4204/4885SLC37A4 1656/4885ALDH1A1 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.